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Abstract 
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Principles: Surgeon's experience is crucial for proper application of sentine! node 
biopsy (SNB) in patients with breast cancer. A 20-30 cases learning curve of sentine! 
node (SN) and axillary lymph node dissection (ALND) was widely practiced. ln order 
to speed up this learning curve, surgeons may be trained intraoperatively by an 
experienced surgeon. The purpose of this report is to evaluate the results of this 
procedure. 
Methods: Patients with one primary invasive breast cancer (cT1-T2[<3 cm]cNO) 
underwent SNB based on lymphoscintigraphy using technetium Tc 99m colloid, 
intraoperative gamma probe detection, with or without blue dye mapping. This was 
followed by completion ALND when SN was positive or not found. SNB was 
performed by one experienced surgeon (teacher) or by 10 junior surgeons trained by 
the experienced surgeon (trainees). Four groups were defined: (i) SNB with 
immediate ALND for the teacher's learning curve, (ii) SNB by the teacher, (iii) SNB by 
the trainees under the teacher's supervision, and (iv) SNB by the trainees alone. 
Results: Between May 1999 and December 2007, a total of 808 evaluable patients 
underwent SNB. The SN identification rate was 98% in the teacher's group, and 99% 
in the trainees' group (p = 0.196). SN were positive in respectively 28% and 29% of 
patients (p = 0.196). The distribution of isolated tumor cells, micrometastases and 
metastases was not statistically different between the teacher's and the trainees' 
groups (p = 0.163). 
Conclusion: These comparable results confirm the success with which the SNB was 
taught. This strategy avoided the 20-30 SNB followed by immediate ALND early 
required per surgeon. 




de Médecine/ BiUM 
CHUV-BHOS - Bugnon 46 
CH-1011 Lausanne 
Introduction 
Axillary staging is the most important prognostic factor for selection of appropriate 
adjuvant therapy, for locoregional recurrence and for long-term survival in breast 
cancer patients and was traditionally achieved by axillary lymph node dissection 
(ALND) [1, 2]. With the trend towards earlier detection and presentation of breast 
cancer, most patients do not have lymphatic metastases at diagnosis. Herein lies an 
irony: with widespread use of breast conservative surgery, the ALND carries a great 
morbidity [3, 4, 5]. 
Methods for accurately staging the axilla remain dominated by sentine! node biopsy 
(SNB), which is now accepted as a standard of breast surgery [6]. The aims of SNB 
include avoiding the unnecessary removal of uninvolved lymph nodes with standard 
ALND, preventing the morbidity of ALND and improving the pathologie examination 
by focusing on fewer lymph nodes [7, 8]. Risks of arm and shoulder morbidity (eg. 
pain, lymphedema and sensory loss), drainage, length of hospital stay, and time to 
resumption of normal day-to-day activities after surgery decrease significantly in 
patients undergoing SNB compared to patients undergoing ALND [2, 9]. 
Using a radiocolloid alone, Krag et al. first reported SNB in 18 out of 22 patients with 
breast cancer [10]. Using vital blue, Giuliano et al. were able to localize SN in 114 out 
of 174 patients (65.5%) [11]. Then the concept that sentine! node (SN) could be 
localized in breast cancer and that it was predictive of the axillary status was 
validated [12, 13, 14, 15]. Moreover it is now established that rates of clinical regional 
recurrence in patients with negative SNB, who had not proceeded to ALND, range 
from 0 to 1.4% [6, 16, 17,]. 
The identification of SN is directly related to the surgeon's experience. Performance 
and technical failure data are correlated with the number of cases. A study 
demonstrated that an average of 23 procedures are required for a surgeon to 
achieve a SNB success rate of 90% and that 53 cases allow to reach 95% [18]. A 20-
30 cases learning curve is widely recommended [19, 20, 21]. 
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We tried to speed up this learning curve, surgeons being trained in operative room by 
one instructor. The purpose of this report is to evaluate the procedure by comparing 
SN identification rates, SN status, the number of micrometastases or metastases of 
patients operated by the teacher and by the trainees. 
Material and methods 
Between May 1999 and December 2007, 808 patients with one primary invasive 
breast cancer (cT1-T2[<3 cm]cNO) underwent a sentine! node biopsy (SNB) with one 
experienced surgeon (teacher) or with 10 junior surgeons, trained by the teacher 
(trainees ), the patients having given their informed consent. 
ln the Centre Hospitalier Universitaire Vaudois and in four community hospitals, four 
groups were defined: (i) SNB with immediate ALND for the teacher's learning curve, 
(ii) SNB by the teacher, (iii) SNB by the trainees under the teacher's supervision and 
(iv) SNB by the trainees alone. Training was based on 5-10 cases per surgeon. The 
criteria of patient selection, the parameters of success of the sentine! node (SN) 
procedure and the lymph node metastases were compared in all groups but the 
reported p-values are only compared between group (ii) and (iv). 
Lymphatic mapping was obtained by peritumoral or periareolar injection of 2-5 ml 
technetium 99m colloid and lymphoscintigraphy, performed the day before surgery. 
Location of SN was achieved in the operative room with a hand-held gamma probe 
(Neoprobe®), with or without peritumorally blue dye injection. SNB was performed 
prior to the breast surgery, allowing an intraoperative examination of the SN using 
the touch imprint cytology technique [22]. Completion ALND of levels 1 and Il was 
performed when SN was positive for metastasis or when the SN could not be 
identified. SN were assessed for the presence of metastases by both hematoxylin 
and eosin (H&E) staining and cytokeratine immuno-histochemistry (IHC). 
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Results 
After having completed his learning curve of 40 sentine! node biopsies (SNB) 
followed by completion axillary lymph node dissection (ALND), the teacher operated 
138 patients. 10 trainees operated 159 patients under the teacher's supervision, and 
then 471 patients alone. 
Patients' characteristics are listed in Table 1. The median age was 56±11 (ranging 
from 28 to 85 years) in the teacher's group and 60±12 (ranging from 26 to 92 years) 
in the trainees' group. Ductal carcinoma was the most frequent type. Stage IC (11-20 
mm) was the most common. Grade 1 differentiation was diagnosed in 38% of 
patients in the teacher's group and in 28% of patients in the trainees' group, whereas 
grade 2 was found in respectively 36% and 53% of patients, and grade 3 in 
respectively 26% and 19% of patients (p = 0.003). 
The SN identification rate of the teacher and the trainees was respectively 98% and 
99% (Table 2). SN was positive for metastasis in 31 % of patients in the teacher's 
group and in 29% in the trainees' group (p=0.092). Then ALND was performed. 
ALND was performed in 3 patients in the teacher's group and in 4 patients in the 
trainees' group, because no SN was detected. Lymph nodes (LN) were negative in 
the 3 patients of the teacher's group, and positive in 3 out of 4 patients in the 
trainees' group. lsolated tumor cells or micrometastases were detected in 130 
patients (54%) and metastases were detected in 113 patients (46%) out of 243 
patients with positive LN. Even if isolated tumor cells and micrometastasis were 
proportionally more frequent in the teacher's group (70%) than in the trainees' group 
(53%) (Table 3), the overall percentage of women with positive LN was not 
statistically different (p = 0.833), thus confirming that the SNB technique was 
correctly taught. Postoperative evaluation revealed distant metastases in 12 patients; 
SN was positive in all of them. 
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Discussion 
The primary aims of breast cancer surgery are to obtain local and regional contrai of 
the cancer and gather sufficient information to make an accurate prediction of the risk 
of distant metastasis in order to guide systemic therapy. This has traditionally been 
achieved by lumpectomy and axillary lymph node dissection (ALND). A meta-
analysis compared mastectomy or lumpectomy plus radiation with or without ALND 
and reported a significant pooled survival benefit of 5.4% (95% Cl 2.7%-8.0%, 
p<0.01) favouring ALND [23]. Although this meta-analysis suggests a significant 
survival benefit with ALND, evolving approaches in surgical management, 
radiotherapy, adjuvant systemic therapy and screening practices may limit the 
magnitude of survival benefit on women treated with current breast cancer therapy 
[24]. Other data tend to diminish the conclusions of this meta-analysis. ln the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 study, a 25-year 
follow-up failed to show a significant difference in overall survival between the groups 
with and without ALND (25% v. 26% respectively) [25]. Rates of distant disease-free 
survival were respectively 46% and 43% in the groups with and without ALND (HR = 
1.10, 95% Cl 0.89-1.35) [25]. Moreover, ALND has significant short- and long-term 
morbidities, the most significant being lymphedema [7]. 
ln comparison, sentine! node biopsy (SNB) is a minimally invasive technique to stage 
the axilla in breast cancer, and randomized trials comparing SNB and ALND have 
demonstrated a significantly reduced morbidity in SNB compared to ALND [2,9,26]. 
Moreover, SNB reflects the status of the axilla in 97-99% of cases [27, 28], and many 
studies validated the technique demonstrating a high sentine! node (SN) identification 
rate (>90%) and low false negative rates (ranging from 5.1 to 9.8%) [6, 13, 27, 29, 
30] (Table 4). When the SN is free of tumor, the probability of non-SN involvement is 
<0.1 % [37]. A further benefit of SNB is the possibility of targeting intensive 
histopathological examination by analysis of multiple sections of the nodes with the 
use of immunohistochemicals (IHC), which increases the sensitivity of detection [7, 
38]. 
Preoperative identification of SN is highly predictive of the success of the subsequent 
procedure [7] thanks to identification of an unexpected drainage route, especially 
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non-axillary LN [15, 39, 40]. ln this series, when SN were detected with the 
radiotracer, the SNB succeeded in 99% of patients. Patient selection, timing as well 
as location of injection of radionucleide may influence the SN identification [41 ]. The 
SN identification rate is higher and the false negative rate is lower when the 
radiocolloide is used alone or in combination with blue dye than when blue dye is 
used alone [35, 42]. This labeling technique with blue dye is now abandoned in our 
breast unit, since it caries a risk of allergy (ranging from trivial skin rashes to life 
threatening anaphylaxis) in 1-2% of patients [43, 44]. 
ln this series, failure to identify SN was probably due to metastases in 3 out of 4 
patients in the trainees' group, since grossly metastatic disease may cause a 
blockage to the flow of lymphatic fluid through the afferent lymphatics. Potential 
candidates for SNB should have clinically negative axillary LN (cNO), or a negative 
core or fine needle aspiration biopsy of any clinically suspicious axillary LN(s) [45]. 
We have no explanation for the other 4 failures of SN identification, even if other 
reasons for failure may include age and high BMI [8, 46, 47], but these parameters 
were not analyzed. 
Adequate surgeon education has been identified as a critical factor for the successful 
application of new surgical procedures, although the required experience still remains 
controversial. Early study of SNB advocated a training set of 60 to 80 cases to 
achieve acceptable SN identification rate and to minimize false-negative events [48]. 
Subsequent studies advocated performance of 20 to 30 consecutive SNB followed by 
ALND and defined a minimal success rate of 85% for the identification of SN based 
on observed learning curves at pioneering institutions [19, 21, 49-52]. Bass et al. 
reported that an average of 23 patients per surgeon is required to achieve a 90±4% 
success rate and that 53 patients are required to obtain a success rate of 95±2% 
[53]. An English structured program called 'New Start' was developed to teach the 
SN technique [2]. Surgeons were trained on-site for 5 cases. Then they had to 
perform an audit series of 25 SNB and immediate Al.ND. The aim of the audit series 
was to verify that the surgeon with the assistance of the multidisciplinary team was 
able to identify the SLN in >90% of patients [2]. The American Society of Breast 
Surgeons SLNB Consensus Statement supports performing 20 cases of SNB and 
ALND and states that the use of mentoring, proctored cases and formai training in 
6 
accredited continuing medical education courses may reduce the persona! case 
experience necessary to achieve optimal results [21]. We may wonder whether it is 
ethical to subject a woman to ALNO, if she is candidate for SNB alone, purely for the 
purposes of surgical education. Along with others, we support the complete abandon 
of the learning curve [54]. The comparable results between the teacher and the 
trainees confirm the success with which the SNB was taught. ln this series, 10 
trainees were enrolled. Traditionally, they would have to operate an average of 250 
patients during their learning curve. Thanks to our mentoring technique, 70% of 
patients (175 of the 250 pNO(sn) patients) were spared of ALNO. 
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Table 1: Patient characteristics 
Teacher Teacher Trainees Trainees Ali p-value 
learning (%) learning taught (%) 
(%) (%) (%) 
Median age (years) 59±12 56±11 59±11 60±12 59±11 0.031 
Stage 
T1a 1 (2) 15 (11) 20 (13) 44 (9) 77(10) 0.236 
T1b 12 (30) 40 (29) 33 (21) 116 (25) 201 (25) 
T1c 17 (43) 62 (45) 78 (49) 233 (49) 390 (48) 
T2 9 (23) 19 (14) 26 (16) 76 (16) 130 (16) 
T3 1 (2) 2 (1) 2 (1) 2 (1) 7 (1) 
Differenciation 
G1 17 (42) 52 (38) 55 (34) 129 (27) 253 (31) 0.003 
G2 15 (38) 49 (35) 71 (45) 249 (53) 384 (48) 
G3 8 (20) 36 (26) 30 (19) 90 (19) 164 (20) 
Unknown 0 (0) 1 (1) 3 (2) 3 (1) 7 (1) 
Histology 
Ductal 32 (80) 110(80) 111 (70) 348 (74) 601 (75) 0.290 
Lobular 4 (10) 16 (12) 18(12) 55 (11) 93 (12) 
Tubulous 3 (8) 7 (5) 9 (6) 19 (4) 38 (5) 
Mucinous 1 (2) 0 (0) 7 (4) 7 (2) 15 (2) 
Ductal & lobular 0 (0) 4 (3) 7 (4) 31 (7) 42 (5) 
Other 0 (0) 1 (1) 7 (4) 11 (2) 19 (2) 
Palpable 
Yes 14 (35) 64 (46) 72 (45) 242 (51) 392 (49) 0.012 
No 26 (65) 74 (54) 79 (50) 211 (45) 390 (48) 
Unknown 0 (0) 0 (0) 8 (5) 18 (4) 26 (3) 
Surgery 
Lurnpectorny 40 (1 OO) 124 (90) 150 (94) 433 (92) 747 (92) <0.001 
Mastectorny 0 (0) 14(10) 9 (6) 38 (8) 61 (8) 
Distant rnetastases 
No 39 (98) 134 (97) 157 (99) 466 (99) 796 (99) 0.123 
Yes 1 (2) 4 (3) 2 (1) 5 (1) 12 (1) 
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Table 2. Sentine! nodes characteristics 
Teacher Teacher Trainees Trainees Ali p-value 
learning (%) learning taught (%) 
(%) (%) (%) 
Identification rate 39 (98) 135 (98) 154 (97) 467 (97) 795 (99) 0.196 
SN not found 1 (2) 3 (2) 5 (3) 4 (1) 13 (2) 0.003 
Metastases 
Positive SN 11 (28) 43 (31) 44 (28) 138 (29) 236 (29) 0.092 
Positive ALND 0 (0) 0 (0) 4 (3) 3 (1) 7 (1) 
with no SN found 
Total 11 (28) 43 (31) 48 (30) 141 (30) 243 (30) 0.833 
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Table 3. lsolated turnor cells, rnicrornetastases and rnetastases in sentine! nodes 
Teacher Teacher Trainees Trainees Ali p-value 
learning (%) learning taught (%) 
(%) (%) (%) 
lsolated turnor cells 0 (0) 9 (21) 6 (13) 22 (16) 37 (15) 0.163 
(IHC) 
Micrornetastases 2 (18) 2 (5) 2 (4) 14 (10) 20 (8) 
(IHC) 
Micrometastases 2 (18) 19 (44) 14 (29) 38 (27) 73 (30) 
(H&E) 
Metastases 7 (64) 13 (30) 26 (54) 67 (47) 20 (8) 
(H&E) 
Total 11(100) 43 (1 OO) 48 (1 OO) 141 (100) 243 
(100) 
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Table 4 : SN identification in the literature 
Author Publication Number SN Fa Ise Negative 
year of identification negative predictive value 
patients Rate[%] [%] [%] 
ln the 
study 
Krag [1 O] 1993 22 82 0 100 
Giuliano [11] 1994 174 66 12 96 
Giuliano [31] 1997 107 93 0 100 
Günther [32] 1997 145 71 10 96 
Veronesi 1997 163 98 5 98 
[12] 
Cox [14] 1998 466 94 1 99 
Krag [15] 1998 443 93 11 96 
Veronesi 1999 376 99 7 94 
[28] 
Fraile [33] 2000 2569 91 2 97 
McMasters 2000 562 90 6 98 
[34] 
Cady [35] 2001 4333 90 5 -
Posther [8] 2005 5327 99 - -
Povoski [36] 2007 371 95 - -
This series 2009 808 98 - -
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